TABLE 2.
Human Cohort 2 Participant Characteristics (n = 7)
Age, y (at start of study) | 36 ± 6 |
Female | 3 (43) |
BMI, kg/m2 | 23 ± 3 |
Plasma profile at baseline (before PCSK9i therapy) | |
PCSK9, ng/mL | 214 ± 121 |
Total cholesterol, mg/dL | 184 ± 45 |
LDL-C, mg/dL | 104 ± 31 |
HDL-C, mg/dL | 65 ± 18 |
Triglycerides, mg/dL | 71 ± 19 |
PCSK9i single injection | |
Alirocumab (75 mg) | 3 |
Evolocumab (140 mg) | 4 |
Values are mean ± SD, n (%), or n.
Abbreviations as in Table 1.